
    
      Patient will be randomized into two treatment groups on a 1:1 ratio. Both groups will be
      treated with the same drugs which is the usual treatment for avoiding renal transplant
      rejection. In one group the CellCept® dose will be adjusted based on MPA concentration value
      which will be monitored periodically; and the second group will be treated with CellCept®
      Fixed Dose (based on the clinical judgment of the treating physician).
    
  